{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T23:17:30Z","timestamp":1791415050138,"version":"4.3.3"},"reference-count":33,"publisher":"American Medical Association (AMA)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Neurol"],"published-print":{"date-parts":[[2025,2,1]]},"abstract":"\n Importance<\/jats:title>\n Increasing numbers of people with multiple sclerosis (MS) use disease-modifying therapy (DMT). Long-term stable disease while taking such medications provides a rationale for considering DMT discontinuation given patient burden, costs, and potential adverse effects of immunomodulating therapy.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To investigate whether first-line DMT can be safely discontinued in patients with long-term stable MS.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This multicenter, rater-blinded, noninferiority randomized clinical trial was conducted between July 1, 2020, and March 20, 2023, at 14 Dutch centers. Data analysis was performed between July 2023 and January 2024. Key inclusion criteria were relapse-onset MS, aged 18 years or older, without relapses, and without substantial magnetic resonance imaging (MRI) activity in the previous 5 years under first-line DMT. Participants were randomized 1:1 to discontinue or continue first-line DMT.<\/jats:p>\n <\/jats:sec>\n \n Intervention<\/jats:title>\n Discontinuation of first-line DMT.<\/jats:p>\n <\/jats:sec>\n \n Main Outcome and Measure<\/jats:title>\n The primary outcome was significant inflammatory disease activity, defined as relapse and\/or 3 or more new T2 lesions or 2 or more contrast-enhancing lesions on brain MRI.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Of 163 potentially eligible participants, 89 participants were included in the trial at the moment of early termination. Forty-four participants (49.4%) were assigned to the continue group and 45 participants (50.6%) were assigned to the discontinue group. Median (IQR) age was 54.0 (49.0-59.0) years, and 60 participants (67.4%) were female. Two participants in the continue group were lost to follow-up. After a median (IQR) follow-up time of 15.3 (11.4-23.9) months, the trial was prematurely terminated because of inflammatory disease activity recurrence above the predefined limit. In total, 8 of 45 participants in the discontinue group (17.8%) vs 0 of 44 participants in the continue group reached the primary end point and had recurrent, mostly radiological inflammation. Two of these 8 participants had a clinical relapse. Median (IQR) time to disease activity was 12.0 (6.0-12.0) months.<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this randomized clinical trial, even in patients with long-term MS stable for over 5 years, first-line DMT discontinuation can lead to recurrence of inflammatory disease activity. Although this study cohort was relatively small, the recurrence of inflammation in the discontinue group was significantly higher than in the continue group and also higher than in the previously published DISCOMS trial, which only included individuals aged 55 years or older. This study provides additional data, especially in a younger population and including longitudinal biomarker measurements, for informed decision-making in cases when treatment discontinuation is considered.<\/jats:p>\n <\/jats:sec>\n \n Trial Registration<\/jats:title>\n \n ClinicalTrials.gov Identifier:\n NCT04260711<\/jats:ext-link>\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamaneurol.2024.4164","type":"journal-article","created":{"date-parts":[[2024,12,9]],"date-time":"2024-12-09T11:00:36Z","timestamp":1733742036000},"page":"123","source":"Crossref","is-referenced-by-count":40,"title":["Discontinuation of First-Line Disease-Modifying Therapy in Patients With Stable Multiple Sclerosis"],"prefix":"10.1001","volume":"82","author":[{"given":"Eline M. E.","family":"Coerver","sequence":"first","affiliation":[{"name":"Multiple Sclerosis Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam Neuroscience, Amsterdam University Medical Center location VUmc, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wing Hee","family":"Fung","sequence":"additional","affiliation":[{"name":"Multiple Sclerosis Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam Neuroscience, Amsterdam University Medical Center location VUmc, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet","family":"de Beukelaar","sequence":"additional","affiliation":[{"name":"Neurology, Albert Schweitzer Hospital, Dordrecht, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willem H.","family":"Bouvy","sequence":"additional","affiliation":[{"name":"Neurology, Diakonessenhuis, Utrecht, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leo R.","family":"Canta","sequence":"additional","affiliation":[{"name":"Neurology, Catharina Hospital, Eindhoven, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver H. H.","family":"Gerlach","sequence":"additional","affiliation":[{"name":"Neurology, Zuyderland Medical Center, Sittard-Geleen, the Netherlands"},{"name":"School for Mental Health and Neuroscience, Maastricht University, Maastricht, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elske","family":"Hoitsma","sequence":"additional","affiliation":[{"name":"Neurology, Alrijne Hospital, Leiden, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erwin L. J.","family":"Hoogervorst","sequence":"additional","affiliation":[{"name":"Neurology, St Antonius Hospital, Utrecht, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigit A.","family":"de Jong","sequence":"additional","affiliation":[{"name":"Multiple Sclerosis Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam Neuroscience, Amsterdam University Medical Center location VUmc, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nynke F.","family":"Kalkers","sequence":"additional","affiliation":[{"name":"Neurology, OLVG, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zo\u00e9 L. E.","family":"van Kempen","sequence":"additional","affiliation":[{"name":"Multiple Sclerosis Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam Neuroscience, Amsterdam University Medical Center location VUmc, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry","family":"L\u00f6venich","sequence":"additional","affiliation":[{"name":"Neurology, St Jans Gasthuis, Weert, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caspar E. P.","family":"van Munster","sequence":"additional","affiliation":[{"name":"Neurology, Amphia Hospital, Breda, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bob W.","family":"van Oosten","sequence":"additional","affiliation":[{"name":"Multiple Sclerosis Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam Neuroscience, Amsterdam University Medical Center location VUmc, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joost","family":"Smolders","sequence":"additional","affiliation":[{"name":"MS Center ErasMS, Neurology & Immunology, Erasmus Medical Center, Rotterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anke","family":"Vennegoor","sequence":"additional","affiliation":[{"name":"Neurology, Flevoziekenhuis, Almere, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther M. P. E.","family":"Zeinstra","sequence":"additional","affiliation":[{"name":"Neurology, Isala Hospital, Meppel, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar","family":"Barrantes-Cepas","sequence":"additional","affiliation":[{"name":"MS Center Amsterdam, Anatomy and Neurosciences, Amsterdam Neuroscience, Amsterdam University Medical Center, location VUmc, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gijs","family":"Kooij","sequence":"additional","affiliation":[{"name":"MS Center Amsterdam, Molecular Cell Biology and Immunology, Amsterdam Neuroscience, Amsterdam University Medical Center, location VUmc, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Menno M.","family":"Schoonheim","sequence":"additional","affiliation":[{"name":"MS Center Amsterdam, Anatomy and Neurosciences, Amsterdam Neuroscience, Amsterdam University Medical Center, location VUmc, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgit I.","family":"Lissenberg-Witte","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Data Science, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte E.","family":"Teunissen","sequence":"additional","affiliation":[{"name":"Neurochemistry Laboratory, Department of Clinical Chemistry, Amsterdam Neuroscience, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bastiaan","family":"Moraal","sequence":"additional","affiliation":[{"name":"MS Center Amsterdam, Radiology & Nuclear Medicine, Amsterdam Neuroscience, Amsterdam University Medical Center location VUmc, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederik","family":"Barkhof","sequence":"additional","affiliation":[{"name":"MS Center Amsterdam, Radiology & Nuclear Medicine, Amsterdam Neuroscience, Amsterdam University Medical Center location VUmc, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands"},{"name":"Queen Square Institute of Neurology and Centre for Medical Image Computing, University College London, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard M. J.","family":"Uitdehaag","sequence":"additional","affiliation":[{"name":"Multiple Sclerosis Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam Neuroscience, Amsterdam University Medical Center location VUmc, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jop","family":"Mostert","sequence":"additional","affiliation":[{"name":"Neurology, Rijnstate Hospital, Arnhem, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joep","family":"Killestein","sequence":"additional","affiliation":[{"name":"Multiple Sclerosis Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam Neuroscience, Amsterdam University Medical Center location VUmc, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva M. M.","family":"Strijbis","sequence":"additional","affiliation":[{"name":"Multiple Sclerosis Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam Neuroscience, Amsterdam University Medical Center location VUmc, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"2","key":"noi240075r1","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1111\/ene.13536","article-title":"ECTRIMS\/EAN guideline on the pharmacological treatment of people with multiple sclerosis.","volume":"25","author":"Montalban","year":"2018","journal-title":"Eur J Neurol"},{"issue":"9","key":"noi240075r2","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1212\/01.wnl.0000335764.14513.1a","article-title":"Incidental MRI anomalies suggestive of multiple sclerosis: the radiologically isolated syndrome.","volume":"72","author":"Okuda","year":"2009","journal-title":"Neurology"},{"issue":"1","key":"noi240075r3","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/S1474-4422(22)00184-3","article-title":"Ageing and multiple sclerosis.","volume":"22","author":"Graves","year":"2023","journal-title":"Lancet Neurol"},{"issue":"9","key":"noi240075r4","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1177\/1352458520964778","article-title":"Age-related adverse events of disease-modifying treatments for multiple sclerosis: a meta-regression.","volume":"27","author":"Prosperini","year":"2021","journal-title":"Multiple Sclerosis"},{"issue":"8","key":"noi240075r5","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.1111\/ene.15862","article-title":"Association between age and inflammatory disease activity on magnetic resonance imaging in relapse onset multiple sclerosis during long-term follow-up.","volume":"30","author":"Coerver","year":"2023","journal-title":"Eur J Neurol"},{"key":"noi240075r6","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.jns.2018.06.001","article-title":"Predictors of relapse and disability progression in MS patients who discontinue disease-modifying therapy.","volume":"391","author":"Kister","year":"2018","journal-title":"J Neurol Sci"},{"issue":"9","key":"noi240075r7","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1177\/1352458516675751","article-title":"Discontinuation of disease-modifying therapies in multiple sclerosis - clinical outcome and prognostic factors.","volume":"23","author":"Bsteh","year":"2017","journal-title":"Multiple Sclerosis"},{"issue":"10","key":"noi240075r8","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1136\/jnnp-2016-313760","article-title":"Discontinuing disease-modifying therapy in MS after a prolonged relapse-free period: a propensity score-matched study.","volume":"87","author":"Kister","year":"2016","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"noi240075r9","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.msard.2019.07.021","article-title":"Discontinuation of disease-modifying therapy for patients with relapsing-remitting multiple sclerosis: effect on clinical and MRI outcomes.","volume":"35","author":"Yano","year":"2019","journal-title":"Multiple Sclerosis Related Disord"},{"key":"noi240075r10","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2023.107612","article-title":"Discontinuation of disease-modifying therapy in MS patients over 60 years old and its impact on relapse rate and disease progression.","volume":"225","author":"Salavisa","year":"2023","journal-title":"Clin Neurol Neurosurg"},{"issue":"5","key":"noi240075r11","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1111\/ene.14705","article-title":"Quantifying the risk of disease reactivation after interferon and glatiramer acetate discontinuation in multiple sclerosis: the VIAADISC score.","volume":"28","author":"Bsteh","year":"2021","journal-title":"Eur J Neurol"},{"issue":"7","key":"noi240075r12","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/S1474-4422(23)00154-0","article-title":"Risk of new disease activity in patients with multiple sclerosis who continue or discontinue disease-modifying therapies (DISCOMS): a multicentre, randomised, single-blind, phase 4, non-inferiority trial.","volume":"22","author":"Corboy","year":"2023","journal-title":"Lancet Neurol"},{"issue":"5","key":"noi240075r13","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1177\/1352458513502399","article-title":"Interferon beta failure predicted by EMA criteria or isolated MRI activity in multiple sclerosis.","volume":"20","author":"Prosperini","year":"2014","journal-title":"Mult Scler"},{"issue":"Pt 5","key":"noi240075r14","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1093\/brain\/124.5.962","article-title":"The Multiple Sclerosis Impact Scale (MSIS-29): a new patient-based outcome measure.","volume":"124","author":"Hobart","year":"2001","journal-title":"Brain"},{"issue":"7","key":"noi240075r15","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1001\/archneur.1996.00550070080014","article-title":"The measurement of fatigue in patients with multiple sclerosis. a multidimensional comparison with patients with chronic fatigue syndrome and healthy subjects.","volume":"53","author":"Vercoulen","year":"1996","journal-title":"Arch Neurol"},{"issue":"6","key":"noi240075r16","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","article-title":"The MOS 36-item short-form health survey (SF-36). I. conceptual framework and item selection.","volume":"30","author":"Ware","year":"1992","journal-title":"Med Care"},{"issue":"3","key":"noi240075r17","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1177\/1352458517698052","article-title":"Disability progression markers over 6-12?years in interferon-\u00df-treated multiple sclerosis patients.","volume":"24","author":"R\u00edo","year":"2018","journal-title":"Multiple Sclerosis"},{"issue":"2","key":"noi240075r18","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1212\/WNL.0000000000002830","article-title":"Assessing response to interferon-\u00df in a multicenter dataset of patients with MS.","volume":"87","author":"Sormani","year":"2016","journal-title":"Neurology"},{"issue":"8","key":"noi240075r19","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/S1474-4422(21)00095-8","article-title":"2021 MAGNIMS-CMSC-NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis.","volume":"20","author":"Wattjes","year":"2021","journal-title":"Lancet Neurol"},{"issue":"6","key":"noi240075r20","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1515\/cclm-2022-0007","article-title":"Pre-analytical stability of serum biomarkers for neurological disease: neurofilament-light, glial fibrillary acidic protein and contactin-1.","volume":"60","author":"van Lierop","year":"2022","journal-title":"Clin Chem Lab Med"},{"issue":"10","key":"noi240075r21","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1177\/13524585231188625","article-title":"Serum glial fibrillary acidic protein in natalizumab-treated relapsing-remitting multiple sclerosis: an alternative to neurofilament light.","volume":"29","author":"Wessels","year":"2023","journal-title":"Multiple Sclerosis"},{"issue":"19","key":"noi240075r22","doi-asserted-by":"publisher","first-page":"e1898","DOI":"10.1212\/WNL.0000000000012752","article-title":"Serum neurofilament light association with progression in natalizumab-treated patients with relapsing-remitting multiple sclerosis.","volume":"97","author":"Bridel","year":"2021","journal-title":"Neurology"},{"issue":"9","key":"noi240075r23","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000209357","article-title":"Temporal relationship between serum neurofilament light chain and radiologic disease activity in patients with multiple sclerosis.","volume":"102","author":"Fox","year":"2024","journal-title":"Neurology"},{"issue":"6","key":"noi240075r24","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1001\/jama.2022.25080","article-title":"Conditional power: how likely is trial success?","volume":"329","author":"Saville","year":"2023","journal-title":"JAMA"},{"issue":"12","key":"noi240075r25","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1177\/1352458519866613","article-title":"Age-related decreases in relapses among adults with relapsing-onset multiple sclerosis.","volume":"26","author":"Schwehr","year":"2020","journal-title":"Multiple Sclerosis"},{"issue":"12","key":"noi240075r26","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1136\/jnnp.2008.145805","article-title":"Relapses in multiple sclerosis are age- and time-dependent.","volume":"79","author":"Tremlett","year":"2008","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"9","key":"noi240075r27","doi-asserted-by":"publisher","first-page":"2619","DOI":"10.1007\/s00415-020-09895-0","article-title":"Gadolinium enhancement on cranial MRI in multiple sclerosis is age dependent.","volume":"267","author":"Koch","year":"2020","journal-title":"J Neurol"},{"issue":"1","key":"noi240075r28","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.jns.2005.08.006","article-title":"Age-related gadolinium-enhancement of MRI brain lesions in multiple sclerosis.","volume":"239","author":"Tortorella","year":"2005","journal-title":"J Neurol Sci"},{"issue":"13","key":"noi240075r29","doi-asserted-by":"publisher","first-page":"e1334","DOI":"10.1212\/WNL.0000000000012603","article-title":"Association of age with contrast-enhancing lesions across the multiple sclerosis disease spectrum.","volume":"97","author":"Koch","year":"2021","journal-title":"Neurology"},{"issue":"8","key":"noi240075r30","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.1111\/ene.15862","article-title":"Association between age and inflammatory disease activity on magnetic resonance imaging in relapse onset multiple sclerosis during long-term follow-up.","volume":"30","author":"Coerver","year":"2023","journal-title":"Eur J Neurol"},{"issue":"10","key":"noi240075r31","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1007\/s40263-023-01038-z","article-title":"Stopping disease-modifying treatments in multiple sclerosis: a systematic review and meta-analysis of real-world studies.","volume":"37","author":"Prosperini","year":"2023","journal-title":"CNS Drugs"},{"issue":"9","key":"noi240075r32","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/j.it.2020.07.007","article-title":"The role of astrocytes in CNS inflammation.","volume":"41","author":"Giovannoni","year":"2020","journal-title":"Trends Immunol"},{"issue":"5","key":"noi240075r33","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1177\/1352458512443092","article-title":"Neurofilaments as biomarkers in multiple sclerosis.","volume":"18","author":"Teunissen","year":"2012","journal-title":"Multiple Sclerosis"}],"container-title":["JAMA Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/articlepdf\/2827731\/jamaneurology_coerver_2024_oi_240075_1738707037.84078.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T11:02:18Z","timestamp":1739185338000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/fullarticle\/2827731"}},"subtitle":["The DOT-MS Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2025,2,1]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaneurol.2024.4164","relation":{},"ISSN":["2168-6149"],"issn-type":[{"value":"2168-6149","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2,1]]}}}